This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Obesity represents a major risk factor for diseases such as type 2 diabetes, cardiovascular disease and certain types of cancer. The hypothalamus in the brain is the central regulator of food intake and thus is a key target for anti-obesity drugs. Ghrelin is a peripheral hormone that acts on hypothalamic neurons to increase food intake. Human studies have shown that infusing ghrelin increases food intake and decreases energy expenditure. However, no human studies have been undertaken to test whether a ghrelin antagonist will have the opposite effects i.e. will decrease food intake. This proposal will evaluate the effectiveness of ghrelin antagonist in decreasing appetite and adiposity and improving insulin sensitivity.
NIH ExPorter
NIH ExPorter